Lumida
/ASH
⌘K
Ashland Inc

Ashland Inc

ASH
$70.91USD↑+0.30%+0.21 today

MARKET CAP

3.2B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$68 – $72

52W RANGE

$46
$78

AI Summary

Stalk
Sell NowMedium

Price has snapped decisively below the broken consolidation floor around $72.30–72.70 and rolled through the 9- and 20-day EMAs, signaling a shift to bearish bias. The active Support Failure pattern indicates buyers can no longer absorb supply, and within a Stage 4 distribution context this raises the risk of accelerated downside. Short-term timing favors selling rallies into the former support-turned-resistance zone near $72.30–72.70 or the 20/50 EMA confluence. A sustained reclaim and daily close back above that area would invalidate the bearish setup.

  • ↑Q3 2026 revenue +7% YoY to $497M across all business units.
  • ↑Generated $103M in free cash flow with net leverage down to 2.4x.
  • ↓Adjusted EBITDA declined YoY as low production rates weighed on profits.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Ashland Global Holdings Inc. (NYSE: ASH) is a leading global specialty chemicals company that provides a broad range of products and services to diverse end markets, including life sciences, personal care, and specialty additives. Ashland focuses on high-value applications and innovative solutions, demonstrating resilience amid macroeconomic challenges while adapting to evolving market dynamics. The company's commitment to operational efficiency and strategic investments positions it as a prominent player in the specialty chemicals landscape.

Bull says

  • ↑Q3 2026 revenue +7% YoY to $497M across all business units.
  • ↑Generated $103M in free cash flow with net leverage down to 2.4x.
  • ↑Manufacturing optimization program realized $20M of $60M planned savings.
  • ↑High earnings yield and rising dividend demonstrate strong shareholder value.
  • ↑New product launches in life sciences & personal care boost growth.
  • ↑Operational efficiency and pricing power support potential margin expansion.

Bear says

  • ↓Adjusted EBITDA declined YoY as low production rates weighed on profits.
  • ↓Profit margins remain under pressure, delaying expected margin recovery.
  • ↓Sales growth in China muted, increasing concentration risk in key segments.
  • ↓Calvert City plant disruptions cut production and lowered earnings forecasts.
  • ↓Trades at 45.5x P/E, implying stretched valuation versus peers.
  • ↓Weak price momentum and fierce competition may limit upside prospects.

Investment themes with ASH

High Dividend Yield↓ -0.51%

Companies paying above-average dividends

AVGO · JPM · XOM
Buybacks↓ -0.29%

Companies repurchasing their own shares

C · JCI · WFC

Earnings Call · Q3 2025 · Mgmt. Guidance

Updated 08-14-2026neutral

Transcript signals

Bull points

  • In bio-functional actives, sales were up double digits, supported by a robust commercial pipeline and expanding our capabilities in China. We expect this momentum to become more visible as we begin to lap the prior year customer-specific headwinds going forward.
  • A maturing opportunity pipeline coupled with the improved cost structure is enhancing our ability to drive volume growth. We expect to see the early benefit of these actions in Q4.
  • In bio-functional actives, sales were up double digits, supported by a robust commercial pipeline and expanding our capabilities in China. We expect this momentum to become more visible as we begin to lap the prior year customer-specific headwinds going forward.

Bear points

  • the underlying demand isn't really going to be that something's going to spike up. It's things that are specific to us and our activities. And just to just to build on that, I think that that's right. So on the personal care side, the other element to that Jim spoke to earlier is around lapping some of the company specific items that we talked about last year for bio functional actives.
  • Personal care sales were $147 million in the third quarter, down 16% year over year.
  • Personal care sales were $147 million in the third quarter, down 16% year over year.
Read full transcript analysis ›